Gene therapy holds promise for treating diseases that affect the retina, the light-sensitive layer at the back of the eye, which can cause visual impairment and blindness. Although early attempts at gene therapy have shown effectiveness in treating some retinal diseases, there have been severe adverse effects associated with the treatment. Improvements in delivery systems for therapeutic genes have led to significant progress in the development of gene therapies for retinal diseases.
The retina’s accessibility and ocular barriers make it an ideal target for gene therapy, limiting immune responses and the spread of the therapeutic gene throughout the body. Gene therapy can help treat inherited retinal diseases that were previously considered untreatable and has also shown promise in the treatment of acquired retinal diseases, such as glaucoma. The development of gene therapy approaches for retinal diseases requires consideration of various factors, including the delivery system, route of administration, and target cell type.
Viral vectors, such as adeno-associated viruses and lentiviruses, are commonly used for gene delivery in retinal diseases, while nonviral delivery systems offer alternatives that are more amenable to large-scale manufacturing. Subretinal injections and intravitreal injections are predominant modes of administering viral vectors to the retina, targeting photoreceptors and retinal pigment epithelium. Suprachoroidal injections, a newer approach, offer a safer and easier method of vector delivery, although there is a risk of the vector entering circulation.
Inherited retinal diseases, caused by genetic mutations, can be treated through gene therapy approaches that target specific genes involved in the disease. Animal models have aided researchers in developing gene therapies for these conditions, with recent clinical trials showing promising results for the treatment of various inherited retinal diseases. Acquired retinal diseases, on the other hand, affect a larger portion of the population and require gene therapy approaches that target common pathways disrupted in multiple diseases.
Gene therapy for glaucoma, the leading cause of irreversible blindness in older individuals, has shown potential in reducing intraocular pressure and preventing the loss of retinal ganglion cells. Several gene therapy approaches targeting different risk factors associated with glaucoma have been successful in preclinical studies. Despite the progress in the development of gene therapies for retinal diseases, challenges such as safety concerns, large-scale manufacturing, accessibility, costs, and the need for viable target cells remain.
With ongoing clinical trials and advancements in gene therapy technology, more treatments for retinal diseases are expected to be approved in the near future. Gene therapy offers hope for individuals with retinal diseases by providing potential alternatives to existing treatments and addressing specific genetic mutations underlying these conditions. As research continues to progress, the future of gene therapy for retinal diseases looks promising, with the possibility of additional therapies becoming available to the public within the next few years.
